Back to search

Peptide record

TPDB41239

HTDT-6-2-3-2 Anticancer standard
7 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB41239
HTDT-6-2-3-2
Anticancer
Cancer-related peptides
CancerPPD 2.0
standard
No
A 7-aa standard natural anticancer peptide sequence curated from CancerPPD 2.0, with an available 3D structural model.
Sequence
GPLGAGP
Physicochemical Analysis
C25H41N7O8
RNDCEQHIKMFSTWYV
G
567.64
6.02
0
0
2
-0
0.20
0.171
70.00
Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour
0
0.00
0
Residue Composition
number
1
A
0
R
0
N
0
D
0
C
0
E
0
Q
3
G
0
H
0
I
1
L
0
K
0
M
0
F
2
P
0
S
0
T
0
W
0
Y
0
V
Amino Acid Distribution
A: 1 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 3 H: 0 I: 0 L: 1 K: 0 M: 0 F: 0 P: 2 S: 0 T: 0 W: 0 Y: 0 V: 0
Chemical Descriptors
7
C25H41N7O8
567.64
6.02
-0
0.20
0.171
Free
L
Linear
Free
Anticancer
Enteromorpha prolifera
Evidence Records 3 records
Evidence 1 Activity

Activity

IC50
IC50 = 0.3686 ± 0.0935 mg/mL
Anticancer
0.3686

Target

Lung Cancer
NCI-H-460
Lung

Assay & Model

CCK-8 assay
48-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2022

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50 = 1.2564 ± 0.0548 mg/mL
Anticancer
1.2564

Target

Liver Cancer
HepG-2
Liver

Assay & Model

CCK-8 assay
48-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2022
Evidence 3 Activity

Activity

IC50
IC50 = 0.9867 ± 0.0857 mg/mL
Anticancer
0.9867

Target

Lung Cancer
A-549
Lung

Assay & Model

CCK-8 assay
48-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2022